← Back to Search

Vasopeptidase Inhibitor

Firibastat for High Blood Pressure (FRESH Trial)

Phase 3
Waitlist Available
Led By George Bakris, MD
Research Sponsored by Quantum Genomics SA
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from day 1 to day 84
Awards & highlights

Summary

This trial tests firibastat, a twice-daily pill, in adults with high blood pressure that isn't controlled by their current medications. The goal is to see if firibastat can help lower their blood pressure over a few months. Firibastat has shown efficacy in lowering blood pressure in previous studies.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from day 1 to day 84
This trial's timeline: 3 weeks for screening, Varies for treatment, and from day 1 to day 84 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Systolic Blood Pressure at office (mmHg)
Secondary outcome measures
Diastolic Blood Pressure at office (mmHg)
Mean 24-hour ambulatory Diastolic Blood Pressure (mmHg)
Mean 24-hour ambulatory Systolic Blood Pressure (mmHg)

Side effects data

From 2021 Phase 2 trial • 295 Patients • NCT03715998
4%
Hypotension
3%
Coronary artery disease
3%
Dizziness
3%
rash maculo-papular
3%
COVID-19
2%
Epistaxis
2%
Orthostatic hypotension
2%
Hypertension
2%
Myalgia
2%
Cardiac failure
2%
Chest pain
2%
Contusion
2%
Dressler's syndrome
2%
Dermatitis Allergic
2%
Ecchymosis
2%
Skin exfoliation
1%
Dypsnoea
1%
Vascular stent trombosis
1%
Aortic valve incompetence
1%
Retinal Detachment
1%
Death
1%
COVID19
1%
Ischaemic stroke
1%
Ventricule rupture
1%
Chest pain or chest discomfort (non cardiac)
1%
Cough
1%
Periprocedural myocadial infarction
1%
Cardiac tamponade
1%
Myocardial Infarction
1%
Diarrhea
1%
Hyperkalemia
1%
Liver disorder
100%
80%
60%
40%
20%
0%
Study treatment Arm
Group 1: Firibastat 100 mg
Group 2: Firibastat 500 mg
Group 3: Ramipril 5 mg

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: FiribastatExperimental Treatment1 Intervention
Capsules
Group II: PlaceboPlacebo Group1 Intervention
Matching capsules
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
QGC-001
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Quantum Genomics SALead Sponsor
9 Previous Clinical Trials
1,192 Total Patients Enrolled
George Bakris, MDPrincipal InvestigatorAHA Comprehensive Hypertension Center
6 Previous Clinical Trials
878 Total Patients Enrolled
~100 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top